Effect of nolomirole on monocrotaline-induced heart failure

Pasini Evasio, Cargnioni Anna, Pastore Fiorella, Razzetti Roberta, Bongrani Stefano, Gitti Gian Luca, Ferrari Roberto

Research output: Contribution to journalArticle

Abstract

Neurohormonal activation has been shown to be a major factor in congestive heart failure progression and mortality. The beneficial effects obtained in clinical trials with angiotensin converting enzyme (ACE) inhibitors, β-blockers and aldosterone antagonists have confirmed this hypothesis. 5,6-Diisobutirroyloxy-2-methyl-aminotetraline hydrochloride (nolomirole) is a selective agonist of prejunctional D2-dopaminergic and α 2-adrenergic receptors. The stimulation of these receptors inhibits catecholamine release from sympathetic nerve endings. To confirm that this mechanism can be useful in congestive heart failure, we studied the effects of nolomirole on monocrotaline-induced congestive heart failure. The ACE inhibitor trandolapril was used as reference compound. Rats were given single intraperitoneal injection of either saline (control group; n=20) or monocrotaline (50mgkg-1). Three days later, the monocrotaline- treated animals were randomly allocated (n=50 per group) to oral treatment with distilled water (vehicle group), nolomirole (0.25mgkg-1) twice a day, or trandolapril (0.3mgkg-1) once a day up to sacrifice. On the fourth week after monocrotaline injection, animals with signs of congestive heart failure were sacrificed for evaluation of heart hypertrophy and neuroendocrine alterations. Atrial natriuretic peptide (ANP) and alderosterone were determined by radioimmunoassay in plasma. Tissue norepinephrine concentration was quantified by high-pressure liquid chromatography. Nolomirole and trandolapril significantly reduced (a) hypertrophy of right atria and ventricles, (b) plasma levels of ANP and presence of pleural/peritoneal effusions and (c) norepinephrine depletion of right ventricle. These findings confirmed that nolomirole, like trandolapril, is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure model.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalPharmacological Research
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

trandolapril
Monocrotaline
Heart Failure
Angiotensin-Converting Enzyme Inhibitors
Atrial Natriuretic Factor
Heart Ventricles
Norepinephrine
Catecholamine Receptors
Mineralocorticoid Receptor Antagonists
Nerve Endings
Ascitic Fluid
Cardiomegaly
Pleural Effusion
Heart Atria
Intraperitoneal Injections
Adrenergic Receptors
Hypertrophy
Radioimmunoassay
nolomirole
High Pressure Liquid Chromatography

Keywords

  • D/α agonist
  • Monocrotaline-induced heart failure
  • Nolomirole
  • Trandolapril

ASJC Scopus subject areas

  • Pharmacology

Cite this

Evasio, P., Anna, C., Fiorella, P., Roberta, R., Stefano, B., Luca, G. G., & Roberto, F. (2004). Effect of nolomirole on monocrotaline-induced heart failure. Pharmacological Research, 49(1), 1-5. https://doi.org/10.1016/S1043-6618(03)00246-9

Effect of nolomirole on monocrotaline-induced heart failure. / Evasio, Pasini; Anna, Cargnioni; Fiorella, Pastore; Roberta, Razzetti; Stefano, Bongrani; Luca, Gitti Gian; Roberto, Ferrari.

In: Pharmacological Research, Vol. 49, No. 1, 01.2004, p. 1-5.

Research output: Contribution to journalArticle

Evasio, P, Anna, C, Fiorella, P, Roberta, R, Stefano, B, Luca, GG & Roberto, F 2004, 'Effect of nolomirole on monocrotaline-induced heart failure', Pharmacological Research, vol. 49, no. 1, pp. 1-5. https://doi.org/10.1016/S1043-6618(03)00246-9
Evasio, Pasini ; Anna, Cargnioni ; Fiorella, Pastore ; Roberta, Razzetti ; Stefano, Bongrani ; Luca, Gitti Gian ; Roberto, Ferrari. / Effect of nolomirole on monocrotaline-induced heart failure. In: Pharmacological Research. 2004 ; Vol. 49, No. 1. pp. 1-5.
@article{94c463edb8874d5898385fc5ae8b17e5,
title = "Effect of nolomirole on monocrotaline-induced heart failure",
abstract = "Neurohormonal activation has been shown to be a major factor in congestive heart failure progression and mortality. The beneficial effects obtained in clinical trials with angiotensin converting enzyme (ACE) inhibitors, β-blockers and aldosterone antagonists have confirmed this hypothesis. 5,6-Diisobutirroyloxy-2-methyl-aminotetraline hydrochloride (nolomirole) is a selective agonist of prejunctional D2-dopaminergic and α 2-adrenergic receptors. The stimulation of these receptors inhibits catecholamine release from sympathetic nerve endings. To confirm that this mechanism can be useful in congestive heart failure, we studied the effects of nolomirole on monocrotaline-induced congestive heart failure. The ACE inhibitor trandolapril was used as reference compound. Rats were given single intraperitoneal injection of either saline (control group; n=20) or monocrotaline (50mgkg-1). Three days later, the monocrotaline- treated animals were randomly allocated (n=50 per group) to oral treatment with distilled water (vehicle group), nolomirole (0.25mgkg-1) twice a day, or trandolapril (0.3mgkg-1) once a day up to sacrifice. On the fourth week after monocrotaline injection, animals with signs of congestive heart failure were sacrificed for evaluation of heart hypertrophy and neuroendocrine alterations. Atrial natriuretic peptide (ANP) and alderosterone were determined by radioimmunoassay in plasma. Tissue norepinephrine concentration was quantified by high-pressure liquid chromatography. Nolomirole and trandolapril significantly reduced (a) hypertrophy of right atria and ventricles, (b) plasma levels of ANP and presence of pleural/peritoneal effusions and (c) norepinephrine depletion of right ventricle. These findings confirmed that nolomirole, like trandolapril, is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure model.",
keywords = "D/α agonist, Monocrotaline-induced heart failure, Nolomirole, Trandolapril",
author = "Pasini Evasio and Cargnioni Anna and Pastore Fiorella and Razzetti Roberta and Bongrani Stefano and Luca, {Gitti Gian} and Ferrari Roberto",
year = "2004",
month = "1",
doi = "10.1016/S1043-6618(03)00246-9",
language = "English",
volume = "49",
pages = "1--5",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "1",

}

TY - JOUR

T1 - Effect of nolomirole on monocrotaline-induced heart failure

AU - Evasio, Pasini

AU - Anna, Cargnioni

AU - Fiorella, Pastore

AU - Roberta, Razzetti

AU - Stefano, Bongrani

AU - Luca, Gitti Gian

AU - Roberto, Ferrari

PY - 2004/1

Y1 - 2004/1

N2 - Neurohormonal activation has been shown to be a major factor in congestive heart failure progression and mortality. The beneficial effects obtained in clinical trials with angiotensin converting enzyme (ACE) inhibitors, β-blockers and aldosterone antagonists have confirmed this hypothesis. 5,6-Diisobutirroyloxy-2-methyl-aminotetraline hydrochloride (nolomirole) is a selective agonist of prejunctional D2-dopaminergic and α 2-adrenergic receptors. The stimulation of these receptors inhibits catecholamine release from sympathetic nerve endings. To confirm that this mechanism can be useful in congestive heart failure, we studied the effects of nolomirole on monocrotaline-induced congestive heart failure. The ACE inhibitor trandolapril was used as reference compound. Rats were given single intraperitoneal injection of either saline (control group; n=20) or monocrotaline (50mgkg-1). Three days later, the monocrotaline- treated animals were randomly allocated (n=50 per group) to oral treatment with distilled water (vehicle group), nolomirole (0.25mgkg-1) twice a day, or trandolapril (0.3mgkg-1) once a day up to sacrifice. On the fourth week after monocrotaline injection, animals with signs of congestive heart failure were sacrificed for evaluation of heart hypertrophy and neuroendocrine alterations. Atrial natriuretic peptide (ANP) and alderosterone were determined by radioimmunoassay in plasma. Tissue norepinephrine concentration was quantified by high-pressure liquid chromatography. Nolomirole and trandolapril significantly reduced (a) hypertrophy of right atria and ventricles, (b) plasma levels of ANP and presence of pleural/peritoneal effusions and (c) norepinephrine depletion of right ventricle. These findings confirmed that nolomirole, like trandolapril, is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure model.

AB - Neurohormonal activation has been shown to be a major factor in congestive heart failure progression and mortality. The beneficial effects obtained in clinical trials with angiotensin converting enzyme (ACE) inhibitors, β-blockers and aldosterone antagonists have confirmed this hypothesis. 5,6-Diisobutirroyloxy-2-methyl-aminotetraline hydrochloride (nolomirole) is a selective agonist of prejunctional D2-dopaminergic and α 2-adrenergic receptors. The stimulation of these receptors inhibits catecholamine release from sympathetic nerve endings. To confirm that this mechanism can be useful in congestive heart failure, we studied the effects of nolomirole on monocrotaline-induced congestive heart failure. The ACE inhibitor trandolapril was used as reference compound. Rats were given single intraperitoneal injection of either saline (control group; n=20) or monocrotaline (50mgkg-1). Three days later, the monocrotaline- treated animals were randomly allocated (n=50 per group) to oral treatment with distilled water (vehicle group), nolomirole (0.25mgkg-1) twice a day, or trandolapril (0.3mgkg-1) once a day up to sacrifice. On the fourth week after monocrotaline injection, animals with signs of congestive heart failure were sacrificed for evaluation of heart hypertrophy and neuroendocrine alterations. Atrial natriuretic peptide (ANP) and alderosterone were determined by radioimmunoassay in plasma. Tissue norepinephrine concentration was quantified by high-pressure liquid chromatography. Nolomirole and trandolapril significantly reduced (a) hypertrophy of right atria and ventricles, (b) plasma levels of ANP and presence of pleural/peritoneal effusions and (c) norepinephrine depletion of right ventricle. These findings confirmed that nolomirole, like trandolapril, is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure model.

KW - D/α agonist

KW - Monocrotaline-induced heart failure

KW - Nolomirole

KW - Trandolapril

UR - http://www.scopus.com/inward/record.url?scp=0142215554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142215554&partnerID=8YFLogxK

U2 - 10.1016/S1043-6618(03)00246-9

DO - 10.1016/S1043-6618(03)00246-9

M3 - Article

C2 - 14597145

AN - SCOPUS:0142215554

VL - 49

SP - 1

EP - 5

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -